Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Summary: The discovery that mutations in the EGFR gene are detected in up to 50% of lung adenocarcinoma patients, along with the development of highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently occurring...

Full description

Bibliographic Details
Main Authors: Xiaojing Du, Biwei Yang, Quanlin An, Yehuda G. Assaraf, Xin Cao, Jinglin Xia
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:The Innovation
Subjects:
Cancer
targeted therapy
EGFR inhibitors
drug resistance
mutations
chemoresistance mechanisms
Online Access:http://www.sciencedirect.com/science/article/pii/S266667582100028X

Internet

http://www.sciencedirect.com/science/article/pii/S266667582100028X

Similar Items